HK1252778A1 - 细胞扩增方法和治疗组合物 - Google Patents

细胞扩增方法和治疗组合物 Download PDF

Info

Publication number
HK1252778A1
HK1252778A1 HK18112140.4A HK18112140A HK1252778A1 HK 1252778 A1 HK1252778 A1 HK 1252778A1 HK 18112140 A HK18112140 A HK 18112140A HK 1252778 A1 HK1252778 A1 HK 1252778A1
Authority
HK
Hong Kong
Prior art keywords
methods
mscs
relates
production
enriched
Prior art date
Application number
HK18112140.4A
Other languages
English (en)
Chinese (zh)
Inventor
Balarka BANERJEE
Charlotte Morgan
Graham Vesey
Nicolle Hannah Packer
Original Assignee
Cell Ideas Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903658A external-priority patent/AU2015903658A0/en
Application filed by Cell Ideas Pty Ltd filed Critical Cell Ideas Pty Ltd
Publication of HK1252778A1 publication Critical patent/HK1252778A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18112140.4A 2015-09-08 2016-09-08 细胞扩增方法和治疗组合物 HK1252778A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015903658 2015-09-08
AU2015903658A AU2015903658A0 (en) 2015-09-08 Cell expansion methods and therapeutic compositions

Publications (1)

Publication Number Publication Date
HK1252778A1 true HK1252778A1 (zh) 2019-05-31

Family

ID=58240422

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112140.4A HK1252778A1 (zh) 2015-09-08 2016-09-08 细胞扩增方法和治疗组合物

Country Status (10)

Country Link
US (2) US20180236003A1 (https=)
EP (1) EP3347449A4 (https=)
JP (3) JP6995752B2 (https=)
KR (1) KR20180043834A (https=)
CN (1) CN108348555B (https=)
AU (1) AU2016321448B2 (https=)
CA (1) CA3035931A1 (https=)
HK (1) HK1252778A1 (https=)
TW (1) TWI760313B (https=)
WO (1) WO2017041133A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531269A (ja) * 2015-10-23 2018-10-25 リグスホスピタレットＲｉｇｓｈｏｓｐｉｔａｌｅｔ 脂肪由来幹細胞に基づく幹細胞治療
WO2018213795A1 (en) * 2017-05-18 2018-11-22 The Board Of Trustees Of The Leland Stanford Junior University Targeted in situ therapeutic delivery of secreted factors from stem cells for treatment of damaged tissue
MA52883A (fr) 2018-06-15 2021-05-26 Prieto Manuel Hermida Composition pharmaceutique pour dermatologie et ses utilisations
CN109022360A (zh) * 2018-07-03 2018-12-18 湖南未名三胞转化医学科技有限公司 自体脂肪干细胞共培养促进外周血造血干细胞增殖方法
CN110106142B (zh) * 2019-05-30 2020-05-12 深圳阿尔法生物科技有限公司 一种制备“百亿”级脂肪源再生细胞的生产工艺
CN111073857A (zh) * 2019-12-30 2020-04-28 深圳爱生再生医学科技有限公司 一种治疗关节炎的干细胞生物制品及其制备方法与应用
KR102193175B1 (ko) 2020-04-07 2020-12-18 주식회사 엑소스템텍 통증조절인자를 함유한 줄기세포유래 엑소좀 및 그 용도
CO2020012570A1 (es) 2020-10-08 2022-04-08 Inst Distrital De Ciencia Biotecnologia E Innovacion En Salud Idcbis Método de estimulación de células mesenquimales para inducir expresión de factores inmunomoduladores
US20230365937A1 (en) * 2020-10-26 2023-11-16 Hadasit Medical Research Services And Development Ltd. Mesenchymal stem cells and their culture
WO2022192429A1 (en) * 2021-03-10 2022-09-15 Terasaki Insutitute For Biomedical Innovation Constructs comprising fibrin or other blood products for meat cultivation and other applications
BR102022016233A2 (pt) * 2022-08-16 2024-02-27 Omics Biotecnologia Animal Ltda Concentrado de proteínas e peptídeos derivados de células estromais mesenquimais, método de obtenção e uso de concentrado

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0404656D0 (en) * 2004-03-02 2004-04-07 Univ Manchester Treatment of spinal conditions
WO2008034803A1 (en) * 2006-09-18 2008-03-27 Medizinische Universität Graz Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics
WO2012030968A1 (en) * 2010-08-31 2012-03-08 Renovocyte, LLC Systemic, allogenic stem cell therapies for treatment of diseases in animals
DK2744892T3 (en) 2011-09-23 2019-04-23 Cell Ideas Pty Ltd THERAPEUTICS USING FAT CELLS AND CELL SECRETIONS
US20140219972A1 (en) 2013-02-05 2014-08-07 The Board Of Trustees Of The Leland Stanford Junior University Tissue engineering using progenitor cells to catalyze tissue formation by primary cells
EP3405204B1 (en) * 2016-08-26 2025-06-25 Restem Llc Composition and methods of using umbilical cord lining stem cells

Also Published As

Publication number Publication date
CA3035931A1 (en) 2017-03-16
US20180236003A1 (en) 2018-08-23
WO2017041133A1 (en) 2017-03-16
AU2016321448B2 (en) 2023-02-02
EP3347449A4 (en) 2019-03-20
TW201720922A (zh) 2017-06-16
TWI760313B (zh) 2022-04-11
KR20180043834A (ko) 2018-04-30
JP6995752B2 (ja) 2022-02-04
US20210260129A1 (en) 2021-08-26
CN108348555A (zh) 2018-07-31
JP2022186992A (ja) 2022-12-15
JP2022027928A (ja) 2022-02-14
EP3347449A1 (en) 2018-07-18
CN108348555B (zh) 2022-07-08
AU2016321448A1 (en) 2018-03-15
JP2018526447A (ja) 2018-09-13

Similar Documents

Publication Publication Date Title
HK1252778A1 (zh) 细胞扩增方法和治疗组合物
PH12020550660A1 (en) Cultivation of placenta to isolate exosomes
PH12017501921A1 (en) Novel compounds
MY172073A (en) Bioactive botanical cosmetic compositions and processes for their production
BR112017019412A2 (pt) proteínas ligadoras de tslp
WO2016172658A3 (en) Microbiome regulators and related uses thereof
MX392304B (es) Métodos para mejorar la producción de leche mediante la administración de consorcios microbianos.
HK1222205A1 (zh) 由多能干细胞产生的光感受器和光感受器袓细胞
EP4620521A3 (en) Methods and compositions relating to chondrisomes from cultured cells
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
WO2015016761A8 (en) Mscs in the treatment of inflammatory pulmonary diseases
BR112015023084A2 (pt) anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica
WO2012021845A3 (en) Improved hematopoietic stem and progenitor cell therapy
WO2016024205A8 (en) Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
CO6612271A2 (es) Anticuerpos anti-cd40
HK1255331A1 (zh) 抗pcsk9抗体及其应用
BR112023005376A2 (pt) Composições de oligossacarídeos e métodos de uso
MX384075B (es) Nuevas proteínas específicas para la angiogénesis.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX2015005384A (es) Miembros de union para il-1 beta.
BR112012014066A2 (pt) preparações de combinações com exossomos e corticosteróide
MX2016005824A (es) Metodo de cultivo celular.
NZ741724A (en) Renal cell populations and uses thereof